Anti-HPV-16 E6/E7 TCR
Alternative Names: HPV-16 E6 & E7Latest Information Update: 28 Jun 2020
At a glance
- Originator Kite Pharma; National Cancer Institute (USA)
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical cancer; Head and neck cancer
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Cervical-cancer in USA (Parenteral)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Head-and-neck-cancer in USA (Parenteral)
- 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences